{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:00Z","timestamp":1792783380719,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Jena","id":[{"id":"https:\/\/ror.org\/035rzkx15","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Surviv"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Cannabinoids are compounds that occur naturally in cannabis plants. The objective of this systematic review was to provide an overview of the existing evidence regarding the use of cannabinoids for the management of chemotherapy-induced nausea and vomiting (CINV) in cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature search was conducted in June 2024 in five electronic databases (Embase, Cochrane, PsychInfo, CINAHL, and Medline) to identify studies examining the utilization, efficacy, and potential adverse effects of cannabinoid-based therapy in cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 32 studies comprising 1889 patients suffering from different cancer types were included in the systematic review. Cannabinoid-based therapy involved the oral administration of defined and approved cannabis preparations. Of the 22 studies comparing cannabinoid-based CINV management to now outdated antiemetic therapies, 12 found a significant benefit of cannabinoids in CINV management, and eight out of nine studies comparing cannabinoids to placebo observed such a benefit. Only one of the 32 studies with a risk of bias compared cannabinoids to guideline-based therapy with a 5-HT3 receptor antagonist, an NK1 receptor antagonist, and dexamethasone and demonstrated a benefit of cannabinoids in reducing nausea and vomiting, but the therapy was associated with cannabinoid-related side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>With only one study complying with modern antiemetic standards and considering the risks of side effects, clinical evidence to recommend cannabinoids for the management of CINV is deemed insufficient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Cancer Survivors<\/jats:title>\n                    <jats:p>Cancer patients suffering from CINV might find alleviation using cannabinoids, but heterogenous results and side effects prevent clinical recommendation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11764-025-01876-4","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T18:44:57Z","timestamp":1755024297000},"page":"1296-1317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cannabinoids for the prevention of chemotherapy-induced nausea and vomiting in oncological therapy: a systematic review"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3227-4549","authenticated-orcid":false,"given":"Sarah F.","family":"Kemmner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"D\u00f6rfler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Huebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"issue":"4","key":"1876_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.6004\/jnccn.2012.0048","volume":"10","author":"B Todaro","year":"2012","unstructured":"Todaro B. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw. 2012;10(4):487\u201392.","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"1876_CR2","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1002\/cncr.20230","volume":"100","author":"SM Grunberg","year":"2004","unstructured":"Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics: perception versus reality. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2004;100(10):2261\u2013668.","journal-title":"Cancer: Interdisciplinary International Journal of the American Cancer Society"},{"issue":"1","key":"1876_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00520-018-4464-y","volume":"27","author":"Y Razvi","year":"2019","unstructured":"Razvi Y, Chan S, McFarlane T, McKenzie E, Zaki P, DeAngelis C, et al. ASCO, NCCN, MASCC\/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer. 2019;27(1):87\u201395.","journal-title":"Support Care Cancer"},{"issue":"11","key":"1876_CR4","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1007\/s00520-015-2801-y","volume":"23","author":"C Hernandez Torres","year":"2015","unstructured":"Hernandez Torres C, Mazzarello S, Ng T, Dranitsaris G, Hutton B, Smith S, et al. Defining optimal control of chemotherapy-induced nausea and vomiting\u2014based on patients\u2019 experience. Support Care Cancer. 2015;23(11):3341\u201359.","journal-title":"Support Care Cancer"},{"issue":"9","key":"1876_CR5","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1007\/s00520-015-2809-3","volume":"23","author":"Y Escobar","year":"2015","unstructured":"Escobar Y, Cajaraville G, Virizuela JA, \u00c1lvarez R, Mu\u00f1oz A, Olariaga O, et al. Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study. Support Care Cancer. 2015;23(9):2833\u201340.","journal-title":"Support Care Cancer"},{"issue":"3","key":"1876_CR6","doi-asserted-by":"publisher","first-page":"A12","DOI":"10.7326\/ACPJC-1995-123-3-A12","volume":"123","author":"WS Richardson","year":"1995","unstructured":"Richardson WS, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical question: a key to evidence-based decisions. ACP J Club. 1995;123(3):A12-3.","journal-title":"ACP J Club"},{"key":"1876_CR7","doi-asserted-by":"crossref","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. bmj. 2019;366.","DOI":"10.1136\/bmj.l4898"},{"key":"1876_CR8","unstructured":"Onkologie L. S3-Leitlinie \u201eSupportive Therapie bei onkologischen PatientInnen-Langversion 1.3 \u201c. AWMF-Register-Nummer; 2017."},{"key":"1876_CR9","unstructured":"Onkologie L. S3-Leitlinie Komplement\u00e4rmedizin in der Behandlung onkologischer PatientInnen. 2021, AWMF."},{"issue":"11","key":"1876_CR10","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.annonc.2020.07.020","volume":"31","author":"P Grimison","year":"2020","unstructured":"Grimison P, Mersiades A, Kirby A, Lintzeris N, Morton R, Haber P, et al. Oral THC: CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Ann Oncol. 2020;31(11):1553\u201360.","journal-title":"Ann Oncol"},{"issue":"6","key":"1876_CR11","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/0885-3924(91)90026-Z","volume":"6","author":"M Lane","year":"1991","unstructured":"Lane M, Vogel CL, Ferguson J, Krasnow S, Saiers JL, Hamm J, et al. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage. 1991;6(6):352\u20139.","journal-title":"J Pain Symptom Manage"},{"key":"1876_CR12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/BF00175407","volume":"6","author":"M McCabe","year":"1988","unstructured":"McCabe M, Smith FP, Macdonald JS, Woolley PV, Goldberg D, Schein PS. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest New Drugs. 1988;6:243\u20136.","journal-title":"Invest New Drugs"},{"key":"1876_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/BF00256701","volume":"17","author":"M Pomeroy","year":"1986","unstructured":"Pomeroy M, Fennelly JJ, Towers M. Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother Pharmacol. 1986;17:285\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1876_CR14","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/BF01728184","volume":"64","author":"N Niederle","year":"1986","unstructured":"Niederle N, Sch\u00fctte J, Schmidt C. Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Klin Wochenschr. 1986;64:362\u20135.","journal-title":"Klin Wochenschr"},{"key":"1876_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/BF02934575","volume":"3","author":"S Crawford","year":"1986","unstructured":"Crawford S, Buckman R. Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study. Med Oncol Tumor Pharmacother. 1986;3:39\u201342.","journal-title":"Med Oncol Tumor Pharmacother"},{"issue":"4","key":"1876_CR16","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/00000421-198508000-00013","volume":"8","author":"A Niiranen","year":"1985","unstructured":"Niiranen A, Mattson K. A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol. 1985;8(4):336\u201340.","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"1876_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/j.1552-4604.1984.tb01824.x","volume":"24","author":"VR Sheidler","year":"1984","unstructured":"Sheidler VR, Ettinger DS, Diasio RB, Enterline JP, Brown MD. Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine. J Clin Pharmacol. 1984;24(4):155\u20139.","journal-title":"J Clin Pharmacol"},{"key":"1876_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/BF00257128","volume":"13","author":"ME Heim","year":"1984","unstructured":"Heim ME, Quei\u00dfer W, Altenburg H-P. Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy. Cancer Chemother Pharmacol. 1984;13:123\u20135.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"1876_CR19","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/0277-5379(83)90032-9","volume":"19","author":"AW Hutcheon","year":"1983","unstructured":"Hutcheon AW, Palmer JB, Soukop M, Cunningham D, McArdle C, Welsh J, et al. A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy. Eur J Cancer Clin Oncol. 1983;19(8):1087\u201390.","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"5","key":"1876_CR20","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/bjc.1983.247","volume":"48","author":"S Ahmedzai","year":"1983","unstructured":"Ahmedzai S, Carlyle D, Calder I, Moran F. Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer. 1983;48(5):657\u201363.","journal-title":"Br J Cancer"},{"issue":"6 I","key":"1876_CR21","first-page":"1014","volume":"33","author":"S Kleinman","year":"1983","unstructured":"Kleinman S, Weitzman S, Cassem N, Andrews E. Double blind trial of delta-9-tetrahydrocannabinol (THC) versus placebo as an adjunct to prochlorperazine for chemotherapy-induced vomiting. Curr Therapeutic Res-Clin Experiment. 1983;33(6 I):1014\u20137.","journal-title":"Curr Therapeutic Res-Clin Experiment"},{"key":"1876_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0305-7372(82)80035-2","volume":"9","author":"SE Jones","year":"1982","unstructured":"Jones SE, Durant JR, Greco FA, Robertone A. A multi-institutional phase III study of nabilone vs. placebo in chemotherapy-induced nausea and vomiting. Cancer Treat Rev. 1982;9:45\u20138.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"1876_CR23","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/1097-0142(19820815)50:4<636::AID-CNCR2820500404>3.0.CO;2-4","volume":"50","author":"JT Ungerleider","year":"1982","unstructured":"Ungerleider JT, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. Cancer. 1982;50(4):636\u201345.","journal-title":"Cancer"},{"key":"1876_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0305-7372(82)80032-7","volume":"9","author":"R Johansson","year":"1982","unstructured":"Johansson R, Kilkku P, Groenroos M. A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treat Rev. 1982;9:25\u201333.","journal-title":"Cancer Treat Rev"},{"key":"1876_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0305-7372(82)80036-4","volume":"9","author":"M Levitt","year":"1982","unstructured":"Levitt M. Nabilone vs. placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Cancer Treat Rev. 1982;9:49\u201353.","journal-title":"Cancer Treat Rev"},{"key":"1876_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0305-7372(82)80034-0","volume":"9","author":"JK Wada","year":"1982","unstructured":"Wada JK, Bogdon DL, Gunnell JC, Hum GJ, Gota CH, Rieth TE. Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy. Cancer Treat Rev. 1982;9:39\u201344.","journal-title":"Cancer Treat Rev"},{"issue":"S1","key":"1876_CR27","doi-asserted-by":"publisher","first-page":"38S","DOI":"10.1002\/j.1552-4604.1981.tb02571.x","volume":"21","author":"JA Neidhart","year":"1981","unstructured":"Neidhart JA, Gagen MM, Wilson HE, Young DC. Comparative trial of the antiemetic effects of THC and haloperidol. J Clin Pharmacol. 1981;21(S1):38S-42S.","journal-title":"J Clin Pharmacol"},{"issue":"S1","key":"1876_CR28","doi-asserted-by":"publisher","first-page":"64S","DOI":"10.1002\/j.1552-4604.1981.tb02576.x","volume":"21","author":"LH Einhorn","year":"1981","unstructured":"Einhorn LH, Nagy C, Furnas B, Williams SD. Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol. 1981;21(S1):64S-S69.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"1876_CR29","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1002\/1097-0142(19810401)47:7<1746::AID-CNCR2820470704>3.0.CO;2-4","volume":"47","author":"DJ Shiling","year":"1981","unstructured":"Shiling DJ, Stillman RC, Chang AE, Goldberg NH, Seipp CA, Barofsky I, et al. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer. 1981;47(7):1746\u201351.","journal-title":"Cancer"},{"issue":"S1","key":"1876_CR30","doi-asserted-by":"publisher","first-page":"76S","DOI":"10.1002\/j.1552-4604.1981.tb02578.x","volume":"21","author":"LE Orr","year":"1981","unstructured":"Orr LE, McKernan JF. Antiemetic effect of \u03949-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine. J Clin Pharmacol. 1981;21(S1):76S-80S.","journal-title":"J Clin Pharmacol"},{"issue":"662","key":"1876_CR31","first-page":"449","volume":"91","author":"B Colls","year":"1980","unstructured":"Colls B, Ferry D, Gray A, Harvey V, McQueen E. The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. N Z Med J. 1980;91(662):449\u201351.","journal-title":"N Z Med J"},{"issue":"3","key":"1876_CR32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJM198001173020302","volume":"302","author":"SE Sallan","year":"1980","unstructured":"Sallan SE, Cronin C, Zelen M, Zinberg NE. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med. 1980;302(3):135\u20138.","journal-title":"N Engl J Med"},{"issue":"2\u20133","key":"1876_CR33","first-page":"219","volume":"64","author":"N Steele","year":"1980","unstructured":"Steele N, Gralla RJ, Braun DW Jr, Young CW. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis 1, 2, 3. Cancer Treat Rep. 1980;64(2\u20133):219\u201324.","journal-title":"Cancer Treat Rep"},{"issue":"23","key":"1876_CR34","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1056\/NEJM197906073002302","volume":"300","author":"TS Herman","year":"1979","unstructured":"Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC, et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med. 1979;300(23):1295\u20137.","journal-title":"N Engl J Med"},{"issue":"6","key":"1876_CR35","doi-asserted-by":"publisher","first-page":"819","DOI":"10.7326\/0003-4819-91-6-819","volume":"91","author":"AE Chang","year":"1979","unstructured":"Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I, et al. Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate: a prospective, randomized evaluation. Ann Intern Med. 1979;91(6):819\u201324.","journal-title":"Ann Intern Med"},{"issue":"5","key":"1876_CR36","first-page":"338","volume":"21","author":"JC Kluin-Neleman","year":"1979","unstructured":"Kluin-Neleman JC, Neleman F, Meuwissen O, Maes R. Delta 9-tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancerchemotherapy; a double-blind cross-over trial against placebo. Vet Hum Toxicol. 1979;21(5):338\u201340.","journal-title":"Vet Hum Toxicol"},{"issue":"6","key":"1876_CR37","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-91-6-825","volume":"91","author":"S Frytak","year":"1979","unstructured":"Frytak S, Moertel CG, O\u2019Fallon JR, Rubin J, Creagan ET, O\u2019Connell MJ, et al. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy: a comparison with prochlorperazine and a placebo. Ann Intern Med. 1979;91(6):825\u201330.","journal-title":"Ann Intern Med"},{"issue":"16","key":"1876_CR38","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJM197510162931603","volume":"293","author":"SE Sallan","year":"1975","unstructured":"Sallan SE, Zinberg NE, Frei E III. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med. 1975;293(16):795\u20137.","journal-title":"N Engl J Med"},{"issue":"3","key":"1876_CR39","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1185\/030079907X167525","volume":"23","author":"E Meiri","year":"2007","unstructured":"Meiri E, Jhangiani H, Vredenburgh JJ, Barbato LM, Carter FJ, Yang H-M, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin. 2007;23(3):533\u201343.","journal-title":"Curr Med Res Opin"},{"key":"1876_CR40","doi-asserted-by":"crossref","unstructured":"Sukpiriyagul A, Chartchaiyarerk R, Tabtipwon P, Smanchat B, Prommas S, Bhamarapravatana K, et al. Oral tetrahydrocannabinol (THC): cannabinoid (CBD) cannabis extract adjuvant for reducing chemotherapy-induced nausea and vomiting (CINV): a randomized, double-blinded, placebo-controlled, crossover trial. International Journal of Women\u2019s Health. 2023;1345\u201352.","DOI":"10.2147\/IJWH.S401938"},{"issue":"5","key":"1876_CR41","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/j.1365-2125.2010.03743.x","volume":"70","author":"M Duran","year":"2010","unstructured":"Duran M, P\u00e9rez E, Abanades S, Vidal X, Saura C, Majem M, et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol. 2010;70(5):656\u201363.","journal-title":"Br J Clin Pharmacol"},{"issue":"suppl 5","key":"1876_CR42","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(suppl 5):v119\u201333.","journal-title":"Ann Oncol"},{"issue":"13","key":"1876_CR43","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1200\/JCO.23.02596","volume":"42","author":"IM Braun","year":"2024","unstructured":"Braun IM, Bohlke K, Abrams DI, Anderson H, Balneaves LG, Bar-Sela G, et al. Cannabis and cannabinoids in adults with cancer: ASCO guideline. J Clin Oncol. 2024;42(13):1575\u201393.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1876_CR44","doi-asserted-by":"publisher","first-page":"883","DOI":"10.6004\/jnccn.2017.0117","volume":"15","author":"MJ Berger","year":"2017","unstructured":"Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, et al. NCCN guidelines insights: antiemesis, version 2.2017. J Natl Compr Canc Netw. 2017;15(7):883\u201393.","journal-title":"J Natl Compr Canc Netw"},{"issue":"34","key":"1876_CR45","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1200\/JCO.23.01836","volume":"42","author":"P Grimison","year":"2024","unstructured":"Grimison P, Mersiades A, Kirby A, Tognela A, Olver I, Morton RL, et al. Oral cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: final results of a randomized, placebo-controlled, phase II\/III trial. J Clin Oncol. 2024;42(34):4040\u201350.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1876_CR46","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1177\/0269881120986393","volume":"35","author":"AK Schlag","year":"2021","unstructured":"Schlag AK, Hindocha C, Zafar R, Nutt DJ, Curran HV. Cannabis based medicines and cannabis dependence: a critical review of issues and evidence. J Psychopharmacol. 2021;35(7):773\u201385.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"1876_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-07662-1","volume":"31","author":"J To","year":"2023","unstructured":"To J, Davis M, Sbrana A, Alderman B, Hui D, Mukhopadhyay S, et al. MASCC guideline: cannabis for cancer-related pain and risk of harms and adverse events. Support Care Cancer. 2023;31(4): 202.","journal-title":"Support Care Cancer"}],"container-title":["Journal of Cancer Survivorship"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-025-01876-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11764-025-01876-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-025-01876-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:09:05Z","timestamp":1792231745000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11764-025-01876-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":47,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1876"],"URL":"https:\/\/doi.org\/10.1007\/s11764-025-01876-4","relation":{},"ISSN":["1932-2259","1932-2267"],"issn-type":[{"value":"1932-2259","type":"print"},{"value":"1932-2267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}